BASEPOINT Trademark

Trademark Overview


On Monday, April 13, 2020, a trademark application was filed for BASEPOINT with the United States Patent and Trademark Office. The USPTO has given the BASEPOINT trademark a serial number of 88870009. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, February 21, 2022. This trademark is owned by Abbott Rapid Diagnostics International Unlimited Company. The BASEPOINT trademark is filed in the Pharmaceutical Products category with the following description:

Medical diagnostic test kits comprised of medical diagnostic reagents for testing bodily fluids for use in detecting, diagnosing, screening, and confirming infectious disease, respiratory infection, pregnancy, ovulation, cardiovascular disease, hospital acquired infection, blood borne pathogens, enterics, vector borne pathogens, sexually transmitted infection, tropical disease infection, cancer, drugs, and alcohol; medical diagnostic test strips for use in detecting, diagnosing, screening, and confirming infectious disease, respiratory infection, pregnancy, ovulation, cardiovascular disease, hospital acquired infection, blood borne pathogens, enterics, vector borne pathogens, sexually transmitted infection, tropical disease infection, cancer, drugs, and alcohol; medical diagnostic reagents; diagnostic preparations for medical purposes; testing preparations for medical use, namely, for testing for infectious disease, respiratory infection, pregnancy, ovulation, cardiovascular disease, h...
basepoint

General Information


Serial Number88870009
Word MarkBASEPOINT
Filing DateMonday, April 13, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, February 21, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 25, 2021

Trademark Statements


Goods and ServicesMedical diagnostic test kits comprised of medical diagnostic reagents for testing bodily fluids for use in detecting, diagnosing, screening, and confirming infectious disease, respiratory infection, pregnancy, ovulation, cardiovascular disease, hospital acquired infection, blood borne pathogens, enterics, vector borne pathogens, sexually transmitted infection, tropical disease infection, cancer, drugs, and alcohol; medical diagnostic test strips for use in detecting, diagnosing, screening, and confirming infectious disease, respiratory infection, pregnancy, ovulation, cardiovascular disease, hospital acquired infection, blood borne pathogens, enterics, vector borne pathogens, sexually transmitted infection, tropical disease infection, cancer, drugs, and alcohol; medical diagnostic reagents; diagnostic preparations for medical purposes; testing preparations for medical use, namely, for testing for infectious disease, respiratory infection, pregnancy, ovulation, cardiovascular disease, hospital acquired infection, blood borne pathogens, enterics, vector borne pathogens, sexually transmitted infection, tropical disease infection, cancer, drugs, and alcohol; diagnostic tests in the nature of reagents and assays for testing of body fluids for medical use; medical diagnostic assays; solutions used in medical diagnostic test kits, namely, solutions for medical and clinical use in testing for infectious disease, respiratory infection, pregnancy, ovulation, cardiovascular disease, hospital acquired infection, blood borne pathogens, enterics, vector borne pathogens, sexually transmitted infection, tropical disease infection, cancer, drugs, and alcohol; cartridges containing reagents for medical diagnostic test use; cartridges containing medical diagnostic reagents; test cartridges containing chemical reagents for in vitro diagnostic medical testing; medical reagents contained in a cartridge for medical diagnostic use; in vitro diagnostic reagents contained in pre-filled cartridges for medical use; medical diagnostics tests for the detection, diagnosis, screening, and confirmation of infectious diseases; medical kits comprising reagents and assays for testing for the presence of antigens in blood, human serum, plasma, urine, other biological fluids, and tissue; chromatographic immunoassay tests for medical use; testing kits comprised of medical diagnostic reagents and assays for detecting alcohol and drugs; drug and alcohol testing panels, namely, medical diagnostic reagents and assays for testing bodily fluids for the presence of drugs and alcohol
Pseudo MarkBASE POINT

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, April 21, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAbbott Rapid Diagnostics International Unlimited Company
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressBirkirkara CBD3040
MT

Party NameAbbott Rapid Diagnostics International Unlimited Company
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressBirkirkara CBD3040
MT

Trademark Events


Event DateEvent Description
Tuesday, February 22, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, February 21, 2022ABANDONMENT - NO USE STATEMENT FILED
Tuesday, July 20, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, May 25, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 25, 2021PUBLISHED FOR OPPOSITION
Wednesday, May 5, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 20, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 7, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, April 7, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, April 6, 2021ASSIGNED TO LIE
Wednesday, January 6, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, July 6, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, July 6, 2020NON-FINAL ACTION E-MAILED
Monday, July 6, 2020NON-FINAL ACTION WRITTEN
Monday, June 29, 2020ASSIGNED TO EXAMINER
Tuesday, April 21, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, April 16, 2020NEW APPLICATION ENTERED